patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_324492 | REC_0001601 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 19.8 | 73 | female | 2 | 0 | 4.9 | 5 | sotorasib 960 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:57.238868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938402 | REC_0001602 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 10.1 | 67 | female | 1 | 8 | 4.6 | 1 | entrectinib 600 mg daily | 30.1 | true | MSI-H | 2026-03-15T05:35:57.239122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551747 | REC_0001603 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 3.3 | 88 | female | 1 | 24 | 4.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 5.7 | true | MSS | 2026-03-15T05:35:57.239377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887914 | REC_0001604 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.5 | 65 | male | 0 | 23 | 4.4 | 5 | sotorasib 960 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:57.239627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361011 | REC_0001605 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 12.1 | 69 | female | 1 | 9 | 4.4 | 6 | entrectinib 600 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:35:57.239867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301556 | REC_0001606 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 36 | 12 | 65 | male | 1 | 13 | 3.5 | 2 | entrectinib 600 mg daily | 8.4 | true | MSS | 2026-03-15T05:35:57.240226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845758 | REC_0001607 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 7.6 | 61 | female | 0 | 16 | 5.7 | 2 | alectinib 600 mg BID | 23.5 | false | MSS | 2026-03-15T05:35:57.240477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142464 | REC_0001608 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 34 | 8.2 | 54 | female | 0 | 9 | 6.7 | 2 | pembrolizumab 200 mg q3w | 31.7 | false | MSS | 2026-03-15T05:35:57.240714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983840 | REC_0001609 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13 | 62 | male | 1 | 8 | 7 | 6 | entrectinib 600 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:57.240957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506845 | REC_0001610 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 6.9 | 61 | female | 0 | 16 | 6.5 | 6 | entrectinib 600 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:57.241188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323675 | REC_0001611 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 11.3 | 66 | female | 1 | 17 | 6.1 | 4 | sotorasib 960 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:57.241423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658361 | REC_0001612 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.2 | 66 | male | 1 | 25 | 3.3 | 4 | osimertinib 80 mg daily | 8 | true | MSS | 2026-03-15T05:35:57.241659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165178 | REC_0001613 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15.9 | 71 | female | 1 | 23 | 5.8 | 6 | entrectinib 600 mg daily | 11.9 | true | MSI-H | 2026-03-15T05:35:57.242006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868787 | REC_0001614 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 9 | 82 | female | 1 | 21 | 4.9 | 5 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:57.242239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340179 | REC_0001615 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 11 | 62 | female | 1 | 22 | 3.1 | 2 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:57.242476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678322 | REC_0001616 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 4.8 | 74 | female | 1 | 15 | 6 | 4 | pembrolizumab 200 mg q3w | 11.2 | true | MSS | 2026-03-15T05:35:57.242705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311683 | REC_0001617 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 17.5 | 69 | female | 1 | 11 | 5.4 | 1 | osimertinib 80 mg daily | 5.2 | true | MSS | 2026-03-15T05:35:57.242941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649190 | REC_0001618 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 35 | 8 | 71 | male | 2 | 6 | 6.4 | 3 | pembrolizumab 200 mg q3w | 4.5 | true | MSS | 2026-03-15T05:35:57.243179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949599 | REC_0001619 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 7.2 | 63 | male | 0 | 12 | 6 | 2 | sotorasib 960 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:57.243421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_636832 | REC_0001620 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 17.3 | 69 | female | 1 | 13 | 4 | 5 | osimertinib 80 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:57.243652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114902 | REC_0001621 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 18 | 66 | female | 0 | 19 | 5.5 | 6 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.243882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449897 | REC_0001622 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 14.3 | 61 | male | 0 | 13 | 5.8 | 4 | pembrolizumab 200 mg q3w | 10.7 | true | MSI-H | 2026-03-15T05:35:57.244180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250007 | REC_0001623 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 8.9 | 58 | male | 1 | 11 | 4 | 6 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:57.244423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921718 | REC_0001624 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 14.3 | 41 | male | 0 | 26 | 5 | 2 | alectinib 600 mg BID | 10.9 | true | MSS | 2026-03-15T05:35:57.244661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362282 | REC_0001625 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 4.5 | 68 | female | 1 | 39 | 5.7 | 1 | pembrolizumab 200 mg q3w | 17.3 | false | MSS | 2026-03-15T05:35:57.244889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199376 | REC_0001626 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 34 | 6.9 | 76 | female | 2 | 22 | 3.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 12 | false | MSS | 2026-03-15T05:35:57.245183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960990 | REC_0001627 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.4 | 67 | female | 1 | 9 | 6.8 | 1 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:57.245427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628235 | REC_0001628 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.2 | 68 | female | 0 | 15 | 5.7 | 3 | pembrolizumab 200 mg q3w | 7.4 | false | MSS | 2026-03-15T05:35:57.245655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815680 | REC_0001629 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.2 | 71 | male | 3 | 23 | 6.2 | 6 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:35:57.245890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843884 | REC_0001630 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 8.8 | 71 | female | 0 | 35 | 4.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:35:57.246118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638099 | REC_0001631 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 15 | 11.3 | 62 | male | 0 | 11 | 4.5 | 2 | osimertinib 80 mg daily | 25.1 | false | MSI-H | 2026-03-15T05:35:57.246357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740856 | REC_0001632 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.2 | 74 | male | 2 | 8 | 5 | 7 | sotorasib 960 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:57.246590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235512 | REC_0001633 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.4 | 62 | male | 1 | 18 | 4.3 | 7 | sotorasib 960 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:57.246821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311095 | REC_0001634 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 13.1 | 56 | male | 1 | 13 | 5.7 | 1 | sotorasib 960 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:35:57.247056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157906 | REC_0001635 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 7 | 75 | female | 1 | 3 | 4.8 | 7 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:57.247285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968773 | REC_0001636 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 7.8 | 66 | female | 1 | 18 | 4.8 | 7 | osimertinib 80 mg daily | 7.9 | true | MSS | 2026-03-15T05:35:57.247516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468545 | REC_0001637 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 17.3 | 71 | male | 2 | 10 | 6.5 | 2 | alectinib 600 mg BID | 12.9 | true | MSI-H | 2026-03-15T05:35:57.247750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350950 | REC_0001638 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 13.8 | 80 | female | 1 | 29 | 3.6 | 3 | pembrolizumab 200 mg q3w | 28.5 | false | MSS | 2026-03-15T05:35:57.247984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411963 | REC_0001639 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 13.5 | 58 | female | 1 | 16 | 7.5 | 2 | alectinib 600 mg BID | 15.3 | true | MSI-H | 2026-03-15T05:35:57.248381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569102 | REC_0001640 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.2 | 74 | female | 0 | 7 | 4.2 | 1 | pembrolizumab 200 mg q3w | 20.4 | true | MSS | 2026-03-15T05:35:57.248647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248188 | REC_0001641 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.2 | 65 | male | 1 | 66 | 4.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 23.2 | false | MSS | 2026-03-15T05:35:57.248899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956513 | REC_0001642 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 2.6 | 69 | male | 1 | 52 | 4.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:57.249145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671862 | REC_0001643 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 29 | 8 | 68 | female | 1 | 7 | 3.9 | 0 | pembrolizumab 200 mg q3w | 43.5 | true | MSS | 2026-03-15T05:35:57.249409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342126 | REC_0001644 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.6 | 54 | female | 0 | 14 | 5.5 | 7 | entrectinib 600 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:57.249679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122457 | REC_0001645 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.4 | 56 | female | 0 | 51 | 4.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.6 | false | MSS | 2026-03-15T05:35:57.249940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762900 | REC_0001646 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 18.5 | 70 | male | 0 | 15 | 4.5 | 5 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.250190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485362 | REC_0001647 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 12.9 | 61 | female | 0 | 20 | 5.1 | 0 | osimertinib 80 mg daily | 32.1 | false | MSI-H | 2026-03-15T05:35:57.250429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457509 | REC_0001648 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 13.1 | 73 | female | 0 | 15 | 5.1 | 5 | alectinib 600 mg BID | 15.1 | false | MSI-H | 2026-03-15T05:35:57.250665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341997 | REC_0001649 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.7 | 60 | male | 1 | 11 | 6.7 | 4 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:57.250908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488822 | REC_0001650 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 3.9 | 76 | female | 2 | 15 | 5.5 | 1 | entrectinib 600 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:57.251139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602454 | REC_0001651 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 6.2 | 65 | female | 0 | 23 | 4.8 | 7 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:57.251379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673485 | REC_0001652 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 7.3 | 77 | female | 3 | 23 | 6 | 0 | alectinib 600 mg BID | 22.9 | false | MSS | 2026-03-15T05:35:57.251720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781411 | REC_0001653 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.4 | 61 | male | 1 | 23 | 6.7 | 6 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:57.251962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106569 | REC_0001654 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 24 | 21.4 | 61 | female | 0 | 30 | 3.7 | 0 | pembrolizumab 200 mg q3w | 40.6 | true | MSS | 2026-03-15T05:35:57.252269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874539 | REC_0001655 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 8.6 | 71 | male | 0 | 25 | 6.7 | 1 | osimertinib 80 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:57.252513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601370 | REC_0001656 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 12.1 | 70 | female | 1 | 18 | 6.4 | 1 | entrectinib 600 mg daily | 22.3 | false | MSI-H | 2026-03-15T05:35:57.252747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317176 | REC_0001657 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.6 | 59 | female | 0 | 20 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:35:57.252982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977577 | REC_0001658 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 15 | 71 | female | 2 | 3 | 7.7 | 1 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.253215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_920394 | REC_0001659 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 15.3 | 77 | male | 1 | 8 | 4.2 | 2 | osimertinib 80 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:57.253454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614283 | REC_0001660 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 7.4 | 88 | female | 3 | 44 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 22.2 | false | MSS | 2026-03-15T05:35:57.253686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374919 | REC_0001661 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 16.2 | 67 | female | 1 | 11 | 5.5 | 1 | entrectinib 600 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:35:57.253919+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298451 | REC_0001662 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 10.8 | 77 | female | 1 | 9 | 5.8 | 2 | alectinib 600 mg BID | 21.4 | false | MSS | 2026-03-15T05:35:57.254157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842017 | REC_0001663 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 11.6 | 63 | male | 1 | 18 | 8.4 | 2 | sotorasib 960 mg daily | 19.9 | true | MSI-H | 2026-03-15T05:35:57.254392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830937 | REC_0001664 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.7 | 78 | female | 1 | 22 | 8.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:35:57.254622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459042 | REC_0001665 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16.2 | 64 | female | 0 | 15 | 5.2 | 5 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:57.254910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516779 | REC_0001666 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 14.8 | 83 | female | 2 | 12 | 7 | 7 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:57.255147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964404 | REC_0001667 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.5 | 57 | male | 0 | 14 | 6.2 | 2 | osimertinib 80 mg daily | 27.3 | true | MSS | 2026-03-15T05:35:57.255380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458715 | REC_0001668 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 5.7 | 70 | male | 0 | 17 | 4.6 | 5 | alectinib 600 mg BID | 6.9 | false | MSS | 2026-03-15T05:35:57.255612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157024 | REC_0001669 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 5.9 | 64 | female | 0 | 46 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:35:57.255843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822440 | REC_0001670 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 11.8 | 70 | female | 1 | 15 | 6.6 | 1 | entrectinib 600 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:57.256197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632527 | REC_0001671 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 7.9 | 78 | female | 2 | 11 | 5.8 | 7 | entrectinib 600 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:57.256465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458134 | REC_0001672 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 14.4 | 73 | male | 0 | 22 | 4.2 | 0 | alectinib 600 mg BID | 9.7 | true | MSI-H | 2026-03-15T05:35:57.256705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689706 | REC_0001673 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 6.5 | 71 | female | 1 | 42 | 5.2 | 7 | pembrolizumab 200 mg q3w | 8.2 | false | MSS | 2026-03-15T05:35:57.256939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454923 | REC_0001674 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10.7 | 51 | female | 0 | 13 | 5.1 | 3 | entrectinib 600 mg daily | 7.7 | true | MSS | 2026-03-15T05:35:57.257174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507636 | REC_0001675 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 35 | 8.9 | 70 | female | 3 | 21 | 5.2 | 2 | osimertinib 80 mg daily | 21.2 | true | MSS | 2026-03-15T05:35:57.257411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439869 | REC_0001676 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.3 | 86 | female | 1 | 69 | 7 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.1 | true | MSS | 2026-03-15T05:35:57.257642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649153 | REC_0001677 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.8 | 73 | female | 3 | 10 | 6 | 5 | osimertinib 80 mg daily | 9 | false | MSI-H | 2026-03-15T05:35:57.257874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212127 | REC_0001678 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 4.7 | 65 | female | 0 | 3 | 8 | 6 | osimertinib 80 mg daily | 12.9 | true | MSS | 2026-03-15T05:35:57.258160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680649 | REC_0001679 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 17.6 | 75 | female | 1 | 13 | 6.2 | 3 | sotorasib 960 mg daily | 12.1 | false | MSI-H | 2026-03-15T05:35:57.258401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356554 | REC_0001680 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16 | 63 | male | 1 | 20 | 7 | 7 | alectinib 600 mg BID | 12.4 | true | MSS | 2026-03-15T05:35:57.258640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744384 | REC_0001681 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 11.1 | 55 | male | 1 | 7 | 7.6 | 0 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:57.258890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762757 | REC_0001682 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 7.5 | 61 | female | 1 | 17 | 5 | 1 | pembrolizumab 200 mg q3w | 15.7 | true | MSS | 2026-03-15T05:35:57.259134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714139 | REC_0001683 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 16.4 | 66 | female | 0 | 14 | 3.4 | 2 | osimertinib 80 mg daily | 23.4 | true | MSS | 2026-03-15T05:35:57.259386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645252 | REC_0001684 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 18 | 72 | male | 1 | 16 | 3.6 | 1 | osimertinib 80 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:57.259641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714033 | REC_0001685 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.3 | 73 | female | 2 | 13 | 7.2 | 6 | pembrolizumab 200 mg q3w | 12.1 | false | MSS | 2026-03-15T05:35:57.259885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271283 | REC_0001686 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 14.1 | 80 | female | 1 | 9 | 4.5 | 0 | sotorasib 960 mg daily | 25.6 | true | MSS | 2026-03-15T05:35:57.260205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498967 | REC_0001687 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.7 | 77 | female | 2 | 17 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.1 | false | MSS | 2026-03-15T05:35:57.260452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138305 | REC_0001688 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 7 | 60 | female | 1 | 30 | 6.3 | 6 | sotorasib 960 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:57.260691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437345 | REC_0001689 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 11.6 | 72 | female | 2 | 14 | 5.7 | 2 | osimertinib 80 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:57.260924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896877 | REC_0001690 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 17.1 | 64 | female | 0 | 10 | 6.3 | 5 | osimertinib 80 mg daily | 15.2 | true | MSS | 2026-03-15T05:35:57.261161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148331 | REC_0001691 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.3 | 68 | female | 1 | 21 | 5.6 | 6 | alectinib 600 mg BID | 6.4 | true | MSI-H | 2026-03-15T05:35:57.261510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340286 | REC_0001692 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 14.8 | 71 | female | 2 | 5 | 5.3 | 7 | alectinib 600 mg BID | 8.2 | true | MSI-H | 2026-03-15T05:35:57.261748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367460 | REC_0001693 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.1 | 83 | female | 1 | 14 | 6 | 6 | entrectinib 600 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:57.261982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930208 | REC_0001694 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 8.9 | 58 | male | 0 | 9 | 5.8 | 6 | sotorasib 960 mg daily | 4.3 | true | MSS | 2026-03-15T05:35:57.262215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575419 | REC_0001695 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 10.4 | 71 | female | 1 | 11 | 6.5 | 0 | sotorasib 960 mg daily | 46.7 | true | MSI-H | 2026-03-15T05:35:57.262454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759391 | REC_0001696 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 14.3 | 63 | female | 0 | 9 | 4 | 1 | alectinib 600 mg BID | 21.8 | true | MSS | 2026-03-15T05:35:57.262691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295654 | REC_0001697 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 10.7 | 77 | female | 1 | 22 | 6.1 | 5 | pembrolizumab 200 mg q3w | 9 | false | MSI-H | 2026-03-15T05:35:57.262925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180016 | REC_0001698 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 14.8 | 67 | female | 1 | 27 | 4.8 | 3 | pembrolizumab 200 mg q3w | 10.2 | false | MSS | 2026-03-15T05:35:57.263157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625483 | REC_0001699 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 8.5 | 66 | female | 0 | 15 | 7 | 5 | osimertinib 80 mg daily | 6.7 | true | MSS | 2026-03-15T05:35:57.263388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683563 | REC_0001700 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 3.1 | 76 | female | 2 | 51 | 7.1 | 6 | pembrolizumab 200 mg q3w | 10.6 | true | MSS | 2026-03-15T05:35:57.263614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.